Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Особенности течения сердечно-сосудистых заболеваний и принципы выбора рациональной антигипертензивной терапии у больных хронической обструктивной болезнью легких
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В статье обсуждается взаимное влияние сердечно-сосудистой патологии и заболеваний, сопровождающихся бронхообструктивным синдромом. Особое внимание уделено выбору антигипертензивного препарата у пациентов с хронической обструктивной болезнью легких с учетом отсутствия четких рекомендаций по данному вопросу. Вновь акцентирована возможность применения кардиоселективных b-адреноблокаторов у больных данной группы без негативного влияния на показатели функции внешнего дыхания.
Ключевые слова: артериальная гипертензия, хроническая обструктивная болезнь легких, b-адреноблокаторы, безопасность.
Ключевые слова: артериальная гипертензия, хроническая обструктивная болезнь легких, b-адреноблокаторы, безопасность.
________________________________________________
Interrelationships of cardiovascular diseases and bronchoobstruction-associated conditions are discussed. Special attention is paid to the choice of antihypertensive drug in patients with chronic obstructive pulmonary disease because of lack of guidelines in this sphere. The possibility of use of cardioselective b-blockers without negative influence on pulmonary function parameters is emphasized.
Key words: hypertension, chronic obstructive pulmonary disease, b-blockers, safety.
Полный текст
Список литературы
1. Talikka M, Sierro N, Ivanov NV et al. Genomic impact of cigarette smoke, with application to three smoking-related diseases. Critical Rev Toxicol 2012; 42 (10): 877–89.
2. Wilker EH, Alexeeff SE, Poon A et al. Candidate Genes for Respiratory Disease Associated with Markers of Inflammation and Endothelial Dysfunction in Elderly Men. Atherosclerosis 2009; 206 (2): 480–5.
3. Cui H, Miao D-M, Wei Z-M et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol 2012; 9: 5–10.
4. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Intern J COPD 2009; 4: 337–49.
5. Sidney S, Sorel M, Quesenberry CP Jr et al. COPD and Incident Cardiovascular Disease Hospitalizations and Mortality: Kaiser Permanente Medical Care Program. CHEST 2005; 128: 2068–75.
6. Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16 (1): 63–70.
7. Nussbaumer-Ochsner Y, Rabe KF. Systemic Manifestations of COPD. CHEST 2011; 139 (1): 165–73.
8. Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012; 11: 132–58.
9. Ekstrom MP, Hermansson AB, Strom KE. Effect Of Cardiovascular Drugs On Mortality In Severe Chronic Obstructive Pulmonary Disease: A Time-Dependent Analysis. Am J Respir Crit Care Med 2012; 185: A2263.
10. Lawesa CMM, Thornleyb S, Youngc R et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21 (1): 35–40.
11. Mortensen EM, Copeland LA, Pugh MJV et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10 (1): 45.
12. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005. Issue 4. Art. No.: CD003566. DOI: 10.1002/14651858.CD003566.
13. Salpeter SR, Ormiston TM, Salpeter EE et al. Cardioselective beta-blockers for reversible airway disease. Cochrane Database of Systematic Reviews 2002. Issue 4. Art. No.: CD002992. DOI: 10.1002/14651858.CD002992.
14. Etminan M, Jafari S, Carleton B et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine 2012; 12: 48.
15. Lechat P, Packer M, Chalon S et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomised trials. Circulation 1998; 98: 1184–91.
16. Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318 (7200): 1730–7.
17. Jabbour A, Macdonald PS, Keogh AM et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease: a Randomized Crossover Trial. JACC 2010; 55 (17): 1780–7.
18. Chatterjee S, Biondi-Zoccai G, Abbate A et al. Benefits of b-blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013; 346: f55.
19. Овчаренко С.И., Литвинова И.В., Маколкин В.И. Использование кардиоселективных b-адреноблокаторов у пациентов с артериальной гипертонией и/или ИБС и сопутствующим бронхообструктивным синдромом. Тер. архив. 2007; 79 (9): 12–8.
20. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. под ред. А.С.Белевского. М.: Российское респираторное общество, 2012; с. 62–3.
21. Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2008; 7 (6). Прил. 2.
22. Farsang C, Kiss I, Tykarski A, Narkiewicz K. Treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD). European Society of Hypertension Scientific Newsletter: Update on Hypretension Management 2012; 13: No. 51.
23. Dart RA, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003; 123: 222–43.
24. Cazzola M, Noschese P, D’Amato G, Matera MG. The Pharmacologic Treatment of Uncomplicated Arterial Hypertension in Patients With Airway Dysfunction. Chest 2002; 121: 230–41.
25. Hill NS. Fluid and Electrolyte Considerations in Diuretic Therapy for Hypertensive Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med 1986; 146: 129–33.
26. Mancini GBJ, Noschese P, D’Amato G, Matera MG. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol 2006; 47: 2554–60.
27. Myou S, Fujimura M, Kamio Y et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med 2000; 162: 40–4.
28. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715–25.
29. Toblli JE, DiGennaro F, Giani JF et al. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular Health Risk Management 2012; 8: 151–60.
30. Капустина В.А., Овчаренко С.И., Литвицкий П.Ф. Влияние длительной антиоксидантной терапии N-ацетилцистеином на показатели оксидативного стресса у больных хронической обструктивной болезнью легких. Фарматека. 2010; 20: 84–9.
31. Akçay A, Acar G, Kurutaş E et al. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Turk Kardiyol Dern Ars 2010; 38 (4): 244–9.
32. Kus K, Gajda M, Pyka-Fosciak G et al. The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009; 60 (4): 163–5.
2. Wilker EH, Alexeeff SE, Poon A et al. Candidate Genes for Respiratory Disease Associated with Markers of Inflammation and Endothelial Dysfunction in Elderly Men. Atherosclerosis 2009; 206 (2): 480–5.
3. Cui H, Miao D-M, Wei Z-M et al. Prevalence of cardiovascular disease in subjects hospitalized due to chronic obstructive pulmonary disease in Beijing from 2000 to 2010. J Geriatr Cardiol 2012; 9: 5–10.
4. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Intern J COPD 2009; 4: 337–49.
5. Sidney S, Sorel M, Quesenberry CP Jr et al. COPD and Incident Cardiovascular Disease Hospitalizations and Mortality: Kaiser Permanente Medical Care Program. CHEST 2005; 128: 2068–75.
6. Curkendall SM, DeLuise C, Jones JK et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16 (1): 63–70.
7. Nussbaumer-Ochsner Y, Rabe KF. Systemic Manifestations of COPD. CHEST 2011; 139 (1): 165–73.
8. Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012; 11: 132–58.
9. Ekstrom MP, Hermansson AB, Strom KE. Effect Of Cardiovascular Drugs On Mortality In Severe Chronic Obstructive Pulmonary Disease: A Time-Dependent Analysis. Am J Respir Crit Care Med 2012; 185: A2263.
10. Lawesa CMM, Thornleyb S, Youngc R et al. Statin use in COPD patients is associated with a reduction in mortality: a national cohort study. Prim Care Respir J 2012; 21 (1): 35–40.
11. Mortensen EM, Copeland LA, Pugh MJV et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10 (1): 45.
12. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2005. Issue 4. Art. No.: CD003566. DOI: 10.1002/14651858.CD003566.
13. Salpeter SR, Ormiston TM, Salpeter EE et al. Cardioselective beta-blockers for reversible airway disease. Cochrane Database of Systematic Reviews 2002. Issue 4. Art. No.: CD002992. DOI: 10.1002/14651858.CD002992.
14. Etminan M, Jafari S, Carleton B et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulmonary Medicine 2012; 12: 48.
15. Lechat P, Packer M, Chalon S et al. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomised trials. Circulation 1998; 98: 1184–91.
16. Freemantle N, Cleland J, Young P et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318 (7200): 1730–7.
17. Jabbour A, Macdonald PS, Keogh AM et al. Differences Between Beta-Blockers in Patients With Chronic Heart Failure and Chronic Obstructive Pulmonary Disease: a Randomized Crossover Trial. JACC 2010; 55 (17): 1780–7.
18. Chatterjee S, Biondi-Zoccai G, Abbate A et al. Benefits of b-blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 2013; 346: f55.
19. Овчаренко С.И., Литвинова И.В., Маколкин В.И. Использование кардиоселективных b-адреноблокаторов у пациентов с артериальной гипертонией и/или ИБС и сопутствующим бронхообструктивным синдромом. Тер. архив. 2007; 79 (9): 12–8.
20. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. под ред. А.С.Белевского. М.: Российское респираторное общество, 2012; с. 62–3.
21. Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная терапия и профилактика. 2008; 7 (6). Прил. 2.
22. Farsang C, Kiss I, Tykarski A, Narkiewicz K. Treatment of hypertension in patients with chronic obstructive pulmonary disease (COPD). European Society of Hypertension Scientific Newsletter: Update on Hypretension Management 2012; 13: No. 51.
23. Dart RA, Gollub S, Lazar J et al. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003; 123: 222–43.
24. Cazzola M, Noschese P, D’Amato G, Matera MG. The Pharmacologic Treatment of Uncomplicated Arterial Hypertension in Patients With Airway Dysfunction. Chest 2002; 121: 230–41.
25. Hill NS. Fluid and Electrolyte Considerations in Diuretic Therapy for Hypertensive Patients With Chronic Obstructive Pulmonary Disease. Arch Intern Med 1986; 146: 129–33.
26. Mancini GBJ, Noschese P, D’Amato G, Matera MG. Reduction of Morbidity and Mortality by Statins, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin Receptor Blockers in Patients With Chronic Obstructive Pulmonary Disease. J Am Coll Cardiol 2006; 47: 2554–60.
27. Myou S, Fujimura M, Kamio Y et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med 2000; 162: 40–4.
28. Salpeter S, Ormiston T, Salpeter E. Cardioselective betablocker use in patients with reactive airway disease: a metaanalysis. Ann Intern Med 2002; 137: 715–25.
29. Toblli JE, DiGennaro F, Giani JF et al. Nebivolol: impact on cardiac and endothelial function and clinical utility. Vascular Health Risk Management 2012; 8: 151–60.
30. Капустина В.А., Овчаренко С.И., Литвицкий П.Ф. Влияние длительной антиоксидантной терапии N-ацетилцистеином на показатели оксидативного стресса у больных хронической обструктивной болезнью легких. Фарматека. 2010; 20: 84–9.
31. Akçay A, Acar G, Kurutaş E et al. Beneficial effects of nebivolol treatment on oxidative stress parameters in patients with slow coronary flow. Turk Kardiyol Dern Ars 2010; 38 (4): 244–9.
32. Kus K, Gajda M, Pyka-Fosciak G et al. The effect of nebivolol on atherogenesis in apoE-knockout mice. J Physiol Pharmacol 2009; 60 (4): 163–5.
Авторы
Д.А.Напалков*, А.С.Панферов
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
*dminap@mail.ru
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России
*dminap@mail.ru
________________________________________________
D.A.Napalkov*, A.S.Panferov
*dminap@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.